Please login to the form below

Not currently logged in
Email:
Password:

Roche promotes Sophie Kornowski-Bonnet to head of partnering

The current general manager of Roche Pharma, France, Kornowski-Bonnet takes over from Dan Zabrowski who moves to a new role at the company

Roche has promoted Sophie Kornowski-Bonnet from general manager of Roche Pharma in France to head of partnering.

She takes up her new role on February 1, 2012, when she will relocate to the company's headquarters in Basel, Switzerland.

Kornowski-Bonnet replaces Dan Zabrowski, who is staying with the company and will take over as head of Roche applied science in its diagnostics division in Penzberg, Germany. Zabrowski will also assume his new role on February 1, 2012.

Sophie Kornowski-Bonnet Dan Zabrowski - Roche
Sophie Kornowski-Bonnet and Dan Zabrowski

In her new position, Kornowski-Bonnet will lead the company's efforts in finding suitable opportunities for strategic alliances and partnerships in R&D.

Recent Roche collaborations include a deal with PCT Therapeutics to advance treatment for spinal muscular atrophy and an agreement with several Zurich universities to establish an academic translational research centre.

She will also become part of Roche's corporate executive committee, reporting to Severin Schwan, CEO of the Roche Group.

Schwan said that Kornowski-Bonnet had made “tremendous contributions not only to the business but also to the development of a strong R&D hub in France”.

She has been in her current position for five years, with previous pharma experience including time at both Abbott Diagnostics and Abbott Pharmaceuticals in regulation, research and sales roles.

She also led Sanofi's neurology and psychiatry unit in France before joining MSD, where she established a subsidiary in Israel before leading the company's global marketing in osteoarthiritis and pain.
Zabrowski joined Syntex in 1993, before Roche acquired the company in 1994. He has been with Roche ever since, holding several management positions in pharma development.

Schwan commented: “As head of applied science, Dan will be key for driving this strategically important business with our customers in academia, biotech and pharmaceutical industries.”

16th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics